GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » FCF Yield %

Sage Therapeutics (Sage Therapeutics) FCF Yield % : -59.35 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Sage Therapeutics's Trailing 12-Month Free Cash Flow is $-425.06 Mil, and Market Cap is $716.17 Mil. Therefore, Sage Therapeutics's FCF Yield % for today is -59.35%.

The historical rank and industry rank for Sage Therapeutics's FCF Yield % or its related term are showing as below:

SAGE' s FCF Yield % Range Over the Past 10 Years
Min: -59.4   Med: -15.2   Max: 33.5
Current: -59.35


During the past 12 years, the highest FCF Yield % of Sage Therapeutics was 33.50%. The lowest was -59.40%. And the median was -15.20%.

SAGE's FCF Yield % is ranked worse than
77.38% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs SAGE: -59.35

Sage Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -478.76%.


Sage Therapeutics FCF Yield % Historical Data

The historical data trend for Sage Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics FCF Yield % Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.27 13.16 -15.10 -20.31 -41.59

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.55 -18.73 -44.14 -36.71 -13.42

Competitive Comparison of Sage Therapeutics's FCF Yield %

For the Biotechnology subindustry, Sage Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's FCF Yield % falls into.



Sage Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Sage Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-541.138 / 1301.144812
=-41.59%

Sage Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-37.832 * 4 / 1127.81068
=-13.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sage Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Sage Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (Sage Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Executives
Elizabeth Barrett director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas director, officer: See Remarks ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault officer: Chief Medical Officer C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi officer: Chief Commercial Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates director 88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud officer: Chief Scientific Officer 215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan officer: Chief Business Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook officer: General Counsel 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi officer: See Remarks 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035

Sage Therapeutics (Sage Therapeutics) Headlines

From GuruFocus